primera línea
•
7 RCT
•
hazard ratios of patients treated with anti-EGFR
(cetuximab or panitumumab) were
• not depending on the
BRAF
mutation status for OS
•
RAS WT BRAF MUT 0,97 (0,67-1,41)
•
RAS WT BRAF WT 0,81 (0,7-0,85)
•
interaction test : 0.43
• but were close to significance for PFS
•
RAS WT BRAF MUT 0,86 (0,61-1,21)
•
RAS WT BRAF WT 0,62 (0,55-0,77
•
interaction test
P
-value: 0.07
Pietrantonio F, Petrelli F, Coinu A et al. Predictive role of BRAF mutations in patients with advanced colorectal cancer
receivingcetuximab and panitumumab: a meta-analysis. Eur J Cancer 2015; 51: 587–594.
Rowland A, Dias MM, Wiese MD et al. Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR
